Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gliadel

- PMLiVE

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

A round up from pharma, biotech and healthcare

Biogen Idec building

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Says drug slowed down progression of cognitive decline

- PMLiVE

Eisai to tackle dementia in new US research facility

Aims to introduce a new compound into the clinic by 2020

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Daily Brief: Takeda seals $62bn Shire deal, Autolus IPO, Gottlieb warning

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Shaping healthcare

Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes

- PMLiVE

Shire warms to Takeda’s latest offer, extending deadline

The new offer is £5 per share higher than Takeda’s opening bid

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

- PMLiVE

Will Shire agree to extend Takeda takeover talks?

UK rules mean Shire must agree to extend deadline

- PMLiVE

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links